The Feasibility for Screening for Ovarian Cancer.

Q2 Medicine Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine Pub Date : 2024-08-08 eCollection Date: 2024-08-01

Miyo K Chatanaka, Eleftherios P Diamandis

{"title":"The Feasibility for Screening for Ovarian Cancer.","authors":"Miyo K Chatanaka, Eleftherios P Diamandis","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.Methods: Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.Results: The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.Conclusions: EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.","PeriodicalId":37192,"journal":{"name":"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine","volume":"35 2","pages":"132-135"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.

Methods: Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.

Results: The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.

Conclusions: EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

卵巢癌筛查的可行性。

导言：大多数高级别浆液性卵巢癌（HGSOC）病例诊断较晚，无法进行有效治疗。我们研究了使用 EVA（早期卵巢癌）这一新型分子检测方法进行早期 HGSOC 检测的可行性：方法：比较了 EVA 与之前报道的包括 CA125 在内的卵巢癌检测方法的优缺点，并计算了检测方法的阳性预测值和阴性预测值，以衡量其在临床上的实用性：结果：EVA 和 CA125 的阳性预测值分别为 8.6% 和 6.8%，这是根据 0.5% 的患病率计算得出的。结论：EVA 和 CA125 的阳性预测值分别为 8.6%和 6.8%：EVA和CA125不太可能为高危妇女提供有意义的HGSOC人群筛查方法，因为其预测值会促使妇女不进行这些检查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine Medicine-Biochemistry (medical)

CiteScore

2.30

自引率

0.00%

发文量